2,235
Views
61
CrossRef citations to date
0
Altmetric
Author's View

IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer

, , &
Article: e1027473 | Received 03 Mar 2015, Accepted 03 Mar 2015, Published online: 27 Jul 2015

References

  • Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med 2011; 364:1817-25; PMID:21561347; http://dx.doi.org/10.1056/NEJMoa1011923
  • Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New EnglJ Med 2013; 369:1691-703; PMID:24131140; http://dx.doi.org/10.1056/NEJMoa1304369
  • Lunardi S, Jamieson NB, Lim SY, Griffiths KL, Carvalho-Gaspar M, Al-Assar O, Yameen S, Carter RC, McKay CJ, Spoletini G et al. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget 2014; 5:11064-80; PMID:25415223
  • Billottet C, Quemener C, Bikfalvi A. CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim Biophys Acta 2013; 1836:287-95; PMID:23994549; http://dx.doi.org/10.1016/j.bbcan.2013.08.002
  • Redjimi N, Raffin C, Raimbaud I, Pignon P, Matsuzaki J, Odunsi K, Valmori D, Ayyoub M. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res 2012; 72:4351-60; PMID:22798340; http://dx.doi.org/10.1158/0008-5472.CAN-12-0579
  • Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL. Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin Cancer Res 2013; 19:336-46; PMID:23213058; http://dx.doi.org/10.1158/1078-0432.CCR-11-3314
  • Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P. NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 2012; 72:3735-43; PMID:22593190; http://dx.doi.org/10.1158/0008-5472.CAN-11-4136
  • Dodson LF, Hawkins WG, Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 2011; 3:517-37; PMID:21463193; http://dx.doi.org/10.2217/imt.11.10
  • Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19:145-56; PMID:11134207
  • Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014; 25:719-34; PMID:24856586; http://dx.doi.org/10.1016/j.ccr.2014.04.005